Asian Fund for Cancer Research shared a post on LinkedIn:
“In 2024, significant progress has been made in the research of YIV-906. YIV-906 is a first-of-its-kind botanical drug developed by Dr. Yongqi Zheng, a long-time AFCR-backed scientist at the Yale School of Medicine.
In preclinical models, YIV-906 significantly reduced gastrointestinal side effects in patients with rectal (GI) cancer undergoing chemotherapy and radiotherapy, enhancing the immune system’s response to tumors while protecting the patient’s digestive system.
Donations to support cancer research.
2024 scientific research project progress report.
Snapshot of Cancer Research Progress in 2024.”
More posts featuring Asian Fund for Cancer Research.